Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02270242 · ClinicalTrials.gov registry record · Phase 4
Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention
A Phase 4 study, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- Phase 4
- Development phase
- 9,006
- Enrollment target
NCT02270242: Completed Phase 4 study, sponsored by Icahn School of Medicine at Mount Sinai.
NCT02270242 is a Phase 4 study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 9,006 participants, above the 517-participant average among 9,235 other Phase 4 trials with a reported enrollment target (1642% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02270242, a Phase 4 study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 9,006 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the use of ticagrelor alone versus ticagrelor and aspirin together. Both ticagrelor and aspirin stop platelets from sticking together and forming a blood clot that could block blood flow to the heart. This study will look to determine the effectiveness and safety of ticagrelor alone, compared to ticagrelor plus aspirin in reducing clinically relevant bleeding and in reducing ischemic adverse events among high-risk patients who have had a percutaneous intervention with at least one drug-eluting stent. A patient is considered high-risk if they meet certain clinical and/or anatomic criteria. Up to 9000 subjects will be enrolled at the time of their index PCI. Subjects meeting randomization eligibility criteria at 3 months post enrollment will be randomized to either ticagrelor plus aspirin or ticagrelor plus placebo for an additional 12 months. Follow-up clinic visits will be performed at 3 months, 9 months and 15 months post enrollment.
Primary Outcome
Number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 2, 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding).
Interventions
- DRUG Placebo
- DRUG Aspirin
- DRUG ticagrelor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9,006 participants |
| Start Date | 2015-07 |
| Est. Completion | 2019-07-10 |
| Phase | Phase 4 |
What the finished NCT02270242 record still lists
NCT02270242 is an interventional study that assigns participants to a tested intervention. Its 9,006 participants enrollment target places it among the larger protocols in the corpus, above the 517-participant average among 9,235 other Phase 4 trials with a reported enrollment target (1642% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02270242 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02270242 about?
NCT02270242 is a clinical study titled "Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention". The purpose of this study is to compare the use of ticagrelor alone versus ticagrelor and aspirin together. Both ticagrelor and aspirin stop platelets from sticking together and forming a blood clot that could block blood flow to the heart. This study will look to determine the effectiveness and saf...
What is the current status of trial NCT02270242?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 9,006 participants. The study started on 2015-07. Estimated completion is 2019-07-10.
What interventions are being tested in trial NCT02270242?
The interventions under investigation include: Placebo (DRUG), Aspirin (DRUG), ticagrelor (DRUG).
Who is sponsoring clinical trial NCT02270242?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02270242's enrollment target sits among peer trials
9,006 9th of 2000 higher than 1,992 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02000089 · 9,000 participants · Phase 3
The Cancer of the Pancreas Screening-5 CAPS5)Study
- NCT05612347 · 8,946 participants · NA
Colonoscopy vs Stool Testing for Older Adults With Colon Polyps
- NCT06946355 · 9,119 participants · NA
Food-based Support for Hospitalized Children and Their Families
- NCT05336877 · 8,744 participants
Aveir VR Coverage With Evidence Development Post-Approval Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia